HRP20211908T1 - Upotreba varijanti natriuretskog peptida c-tipa za liječenje osteoartritisa - Google Patents

Upotreba varijanti natriuretskog peptida c-tipa za liječenje osteoartritisa Download PDF

Info

Publication number
HRP20211908T1
HRP20211908T1 HRP20211908TT HRP20211908T HRP20211908T1 HR P20211908 T1 HRP20211908 T1 HR P20211908T1 HR P20211908T T HRP20211908T T HR P20211908TT HR P20211908 T HRP20211908 T HR P20211908T HR P20211908 T1 HRP20211908 T1 HR P20211908T1
Authority
HR
Croatia
Prior art keywords
group
cnp variant
seq
nos
use according
Prior art date
Application number
HRP20211908TT
Other languages
English (en)
Croatian (hr)
Inventor
Charles A. O'neill
Todd M. Oppeneer
Jason K. Pinkstaff
Original Assignee
Biomarin Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc. filed Critical Biomarin Pharmaceutical Inc.
Publication of HRP20211908T1 publication Critical patent/HRP20211908T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2242Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/58Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20211908TT 2015-12-08 2016-12-08 Upotreba varijanti natriuretskog peptida c-tipa za liječenje osteoartritisa HRP20211908T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562264682P 2015-12-08 2015-12-08
EP16852866.9A EP3386531B1 (en) 2015-12-08 2016-12-08 Use of c-type natriuretic peptide variants to treat osteoarthritis
PCT/US2016/065520 WO2017100400A2 (en) 2015-12-08 2016-12-08 Use of c-type natriuretic peptide variants to treat osteoarthritis

Publications (1)

Publication Number Publication Date
HRP20211908T1 true HRP20211908T1 (hr) 2022-03-04

Family

ID=59013378

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20211908TT HRP20211908T1 (hr) 2015-12-08 2016-12-08 Upotreba varijanti natriuretskog peptida c-tipa za liječenje osteoartritisa

Country Status (17)

Country Link
US (2) US11202819B2 (https=)
EP (2) EP4019038A3 (https=)
JP (1) JP7104625B2 (https=)
KR (1) KR102941538B1 (https=)
CN (1) CN108697766A (https=)
AU (2) AU2016365751B2 (https=)
CA (1) CA3007315A1 (https=)
DK (1) DK3386531T3 (https=)
ES (1) ES2901769T3 (https=)
HR (1) HRP20211908T1 (https=)
HU (1) HUE057083T2 (https=)
IL (1) IL259690B2 (https=)
MX (1) MX2018006986A (https=)
PL (1) PL3386531T3 (https=)
PT (1) PT3386531T (https=)
RU (1) RU2759679C2 (https=)
WO (1) WO2017100400A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3400019T (lt) 2016-01-08 2022-12-12 Ascendis Pharma Growth Disorders A/S Cnp provaistai su prie žiedo fragmento prijungtu nešikliu
IL297375B2 (en) 2016-01-08 2024-02-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low NPR–C binding
MX2018008061A (es) 2016-01-08 2018-08-23 Ascendis Pharma Growth Disorders As Profarmacos de peptido natriuretico tipo c (cnp) con porciones portadoras grandes.
IL259827B2 (en) 2016-01-08 2025-07-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low initial NPR-B activity
NZ743487A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with increased nep stability
WO2017118707A1 (en) 2016-01-08 2017-07-13 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with reduced side-effects
HUE062117T2 (hu) 2016-09-29 2023-09-28 Ascendis Pharma Growth Disorders As Kombinációs terápia szabályozott felszabadulású CNP agonistákkal
AU2019260810A1 (en) * 2018-04-27 2020-11-19 Remy Biosciences, Inc. New medical devices, delivery vehicles and manufacturing thereof
EP3923906A1 (en) * 2019-02-11 2021-12-22 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of cnp conjugates
WO2022115563A1 (en) * 2020-11-25 2022-06-02 Prolynx Llc Extended release hydrogel conjugates of c-natriuretic peptides
US20240238428A1 (en) * 2021-05-11 2024-07-18 Texas Tech University System Targeted selenium conjugates as countermeasures for viral and cellular pathogens
AU2022407450A1 (en) * 2021-12-07 2024-07-11 Biomarin Pharmaceutical Inc. CNP Therapy
EP4612167A1 (en) 2022-11-02 2025-09-10 Novo Nordisk A/S Cnp compounds
WO2024104922A1 (en) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Method of improving skeletal muscle function
AU2024240722A1 (en) 2023-03-20 2025-09-18 Ascendis Pharma Growth Disorders A/S Method of treatment of a thoracolumbar deformity in a human subject with achondroplasia
KR20250098109A (ko) * 2023-12-21 2025-07-01 주식회사 펩트론 나트륨이뇨 펩타이드 유사체 및 이의 용도
CN117801123B (zh) * 2024-02-29 2024-05-03 天津凯莱英生物科技有限公司 沃索利肽可溶性中间体、中间体制备方法及沃索利肽的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Cnp類似体ペプチド
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
CN1960757A (zh) * 2004-03-31 2007-05-09 中尾一和 身高增加用组合物
CN1960758B (zh) * 2004-03-31 2014-10-22 中外制药株式会社 关节炎的治疗剂或预防剂
AR069409A1 (es) 2007-11-21 2010-01-20 Biomarin Pharm Inc Variantes de peptidos natriureticos de tipo c
ES2608457T3 (es) * 2009-05-20 2017-04-11 Biomarin Pharmaceutical Inc. Variantes de péptido natriurético de tipo C
JP6055779B2 (ja) * 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ, インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法

Also Published As

Publication number Publication date
JP7104625B2 (ja) 2022-07-21
IL259690A (en) 2018-07-31
HUE057083T2 (hu) 2022-04-28
WO2017100400A2 (en) 2017-06-15
EP3386531B1 (en) 2021-10-13
US12214015B2 (en) 2025-02-04
IL259690B (en) 2022-10-01
CA3007315A1 (en) 2017-06-15
WO2017100400A3 (en) 2017-10-26
RU2759679C2 (ru) 2021-11-16
AU2016365751B2 (en) 2023-12-21
US11202819B2 (en) 2021-12-21
EP3386531A2 (en) 2018-10-17
AU2016365751A1 (en) 2018-06-21
RU2021132347A (ru) 2022-03-24
KR20180088459A (ko) 2018-08-03
RU2018124600A3 (https=) 2020-01-13
KR102941538B1 (ko) 2026-03-19
MX2018006986A (es) 2018-09-05
JP2019505486A (ja) 2019-02-28
PL3386531T3 (pl) 2022-02-28
DK3386531T3 (da) 2022-01-03
PT3386531T (pt) 2021-12-29
CN108697766A (zh) 2018-10-23
ES2901769T3 (es) 2022-03-23
US20190247467A1 (en) 2019-08-15
EP4019038A2 (en) 2022-06-29
US20220160836A1 (en) 2022-05-26
EP4019038A3 (en) 2022-09-28
AU2024201852A1 (en) 2024-04-11
IL259690B2 (en) 2023-02-01
RU2018124600A (ru) 2020-01-13

Similar Documents

Publication Publication Date Title
HRP20211908T1 (hr) Upotreba varijanti natriuretskog peptida c-tipa za liječenje osteoartritisa
JP2019505486A5 (https=)
MY154865A (en) Wearing article
CN103622013A (zh) 一种供关节炎患者食用含骨胶原肽的食品配方
HRP20140888T1 (hr) Humana monoklonalna protutijela za humani il-4
HRP20241491T1 (hr) Pripravci i metode za liječenje homocistinurije
HRP20240951T1 (hr) LjUDSKO PROTUTIJELO PROTIV VRSTA ADAMTS TIPA AGREKANAZE ZA TERAPEUTSKA SREDSTVA KOD BOLESTI VEZANIH UZ AGREKANAZE
Hasani et al. Comparative study of static stretch and hold relax on increasing the motion range of knee extension and flexibility of shortened hamstring muscles of male students in semnan
ES2579828T3 (es) Composición para la prevención y el tratamiento de la artritis reumatoide
BR112020004935A8 (pt) Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular
Luo et al. Finite element analysis of the biomechanical effects of manipulation of lower limb hyperextension on the sacroiliac joint
Habibi et al. Idiopathic chondrolysis in a child: think beyond JIA.
MD3906F1 (en) Method for treating the neurotic enuresis to children
Oleas-Santillán et al. Anterior Hip Dislocation from post-injection gluteal muscular fibrosis: case report
Suthar et al. Orthopaedic aspect of anatomy and radiology of proximal femur
Aerts et al. Mallet thumb: report of a case
Banks et al. Successful treatment of pansclerotic morphea with imatinib mesylate in a pediatric patient
Panotopoulos et al. Orthopedic interventions in patients with hemophilia
Kumar Dry gangrene of fingers and injection site pain following accidental intra-arterial injection: case report
Barati et al. Identifying base position for women’s thoracolumbar fascia ultrasound
CN204501145U (zh) 一种骨科护理关节固定限位防护罩
CN202236861U (zh) 一种预防和治疗风湿病的护膝
Henner et al. Recurrent Legg-Perthes-Calvé disease
CN202802076U (zh) 多功能腕指康复板
Bjornstad Description of a new genus and species of Psebiini Lacordaire, 1868 from South Africa (Coleoptera: Cerambycidae: Cerambycinae)